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Anti-Ab antibodies are being developed as potential treatments for Alzheimer’s disease. Some have dose-
limiting side effects and many do not robustly remove pre-existing amyloid plaques. In this issue of Neuron,
DeMattos et al. (2012) demonstrate that an amyloid plaque-specific antibody removes existing Ab aggre-
gates without side effects.Alzheimer’s disease (AD) is the most
common cause of dementia and we do
not know as yet how to prevent, slow, or
reverse the disease with currently avail-
able drugs. Amyloid-b (Ab) is constantly
produced in the brain, predominantly by
neurons, and is secreted as a monomer.
During most of our life, it is cleared and
does not build up in the brain. However,
in some people that go on to develop
AD, it aggregates in the brain to form
amyloid plaques and cerebral amyloid an-
giopathy (CAA). Ab deposition and the
subsequent aggregation of tau culmi-
nating in the formation of neurofibrillary
tangles are two major pathological hall-
marks of AD. By the time humans begin
to have the earliest clinical symptoms
and signs of AD, the amount of Ab
pathology in the brain is already substan-
tial, probably close to the amount that will
be present in the stage of advanced
dementia due to AD (Jack et al., 2010;
Perrin et al., 2009). Therefore, for those
individuals who already have developed
amyloid plaques and who are still asymp-
tomatic or have very mild dementia,
developing effective therapies that can
effectively remove and decrease toxicity
of pre-existing plaques and CAA without
causing side effects is a major goal.
Many anti-Ab antibodies are being
developed as potential treatments for
AD but success has been limited. A
murine monoclonal antibody to Ab, 3D6,
was shown in several studies to decrease
amyloid plaques and CAA when given
soon after Ab deposition began (Bard
et al., 2000; Schroeter et al., 2008).However, results from a recent phase III
clinical trial using bapineuzumab (the
human equivalent of 3D6) in patients
with mild to moderate AD revealed disap-
pointing results, including lack of clinical
effects, no evidence of plaque removal
(though it appears to have attenuated
further increases in plaques), as well as
provocation of side effects associated
with CAA including edema and hemor-
rhages in the brain (Scheltens et al.,
2012, Clinical Trials on Alzheimer’s
Disease, abstract) (Sperling et al., 2012).
It is unclear whether this particular failure
in a phase III clinical trial is due to inade-
quate timing of treatment (i.e., too late),
lack of adequate target engagement, or
both. Given that the most effective results
on amyloid plaque and CAA removal in
animal models have been obtained when
anti-Ab antibodies are started before Ab
pathology is fully formed in the brain
(Das et al., 2001), discrepancies between
the results from animal models and hu-
mans in plaque removal may stem from
lack of efficacy of the anti-Ab antibody
being used in regard to its ability to actu-
ally remove existing Ab aggregates.
Thus, lack of target engagement along
with side effects may have been a real
issue with this antibody at the doses
used in humans.
In this issue of Neuron, DeMattos et al.
(2012) assessed the mechanism of action
of an Ab plaque-specific antibody, mE8,
which specifically binds to pyroglutamate
Ab in amyloid plaques and which does not
bind to soluble Ab. Pyroglutamate Ab is
formed by truncation of the first twoNeuron 76,N-terminal amino acids of Ab and subse-
quent posttranslational modification of
the third amino acid, glutamate, into pyro-
glutamate by glutaminyl cyclase. Pyroglu-
tamate Ab is known to be more prone to
aggregate, to form oligomers, and to be
more toxic (Jawhar et al., 2011). Pyroglu-
tamate Ab is not normally present in vivo;
it is, however, found in amyloid plaques
(Saido et al., 1996). Herein, DeMattos
et al. (2012) compared the effect of
peripherally administered mE8 with
effects of monoclonal antibody 3D6,
which binds to both soluble and insoluble
forms of Ab in the brain in both preventive
and therapeutic paradigms. When admin-
istered in a transgenic mouse model
(PDAPP) at an age at which there are large
amounts of Ab plaque pathology in the
brain as well as CAA, mE8 strongly
decreased the amount of pre-existing,
accumulated insoluble Ab. This effect
occurred without an increase in the
amount of CAA or microhemorrhages
(Figure 1, right). On the other hand, the
3D6 antibody did not decrease the
amount of insoluble Ab in the brain in old
PDAPP mice with a large amount of pre-
existing amyloid plaques, though it mark-
edly increased CAA and CAA-associated
microhemorrhages. Interestingly, 3D6
worked well in decreasing amyloid pla-
ques and insoluble Ab when given in
a prevention mode, as has been shown
previously (Figure 1, left). Studies like
this, in which a compound is tested in
a model in which the amount of Ab pla-
ques and accumulation in the brain is
comparable to what is seen in humansDecember 6, 2012 ª2012 Elsevier Inc. 859
Figure 1. Ab Plaque-Specific Antibody Removing Plaques without Increasing CAA
Plaque-specific antibody mE8 removes pre-existing Ab plaques without causing increased CAA and ARIA (right). In contrast, 3D6 antibody prevented Ab plaque
formation but could not remove pre-existing plaques in the brain (left). Insets in the left panel are reprinted from Sperling et al. (2011). CAA, cerebral amyloid
angiopathy; ARIA, amyloid-related imaging abnormalities.
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Previewswith AD dementia, have not frequently
been done in this field. The results
strongly suggest that if one is targeting
humans in clinical trials who already
have substantial amyloid deposition, the
design of such trials should be based on
preclinical studies that mimic the human
disease state that one is targeting. The
preclinical results of DeMattos et al.
(2012) would have predicted both little
change in plaque load with bapineuzu-
mab in humans and its effect of increasing
CAA. Thus, utilizingmousemodels can be
useful, if similar stages of pathology are
being compared to the human condition.
When administered prior to amyloid
plaque formation, mE8 did not prevent
Ab plaque deposition. The lack of efficacy860 Neuron 76, December 6, 2012 ª2012 Elsin the prevention trial suggests that mE8 is
not working by blocking seeding of
soluble forms of Ab. It does act on already
formed Ab deposits, presumably because
pyroglutamate Ab is generated after
initial Ab aggregation. In future studies,
it will be important to combine therapies
to both prevent and remove Ab accu-
mulation, for example, by combining
drugs that inhibit Ab production (e.g.,
gamma secretase inhibitors/modulators
and b-site amyloid precursor protein-
cleaving enzyme inhibitors) with therapies
that remove existing plaques. The other
consideration would be to combine thera-
peutic antibodies that lack CAA-associ-
ated side effects and can bind and
neutralize the toxicity of soluble forms ofevier Inc.Ab together with plaque-removing thera-
pies. Such combinations might have the
benefit of preventing new Ab plaque
formation and decreasing Ab toxicity,
while an antibody like mE8 could remove
pre-existing plaques, a potential reservoir
for toxic Ab species.
This study raises some additional ques-
tions that will need to be addressed in
future studies. Behavioral and/or func-
tional studies were not performed in the
DeMattos et al. (2012) study. Therefore,
one cannot tell whether the decrease in
levels of Ab in the mice with pre-existing
plaques are beneficial, neutral, or harmful
to cognition or other brain functions
affected by aggregated Ab. The effect of
the Ab removal is very strong in this study
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However, the effect on actual plaque
load as assessed by anti-Ab staining
was not significant in the 23-month-old
PDAPP mice studied. This may be due
to the fact that even though large amounts
of Ab were removed from the brain, the
plaque load by staining was already so
high, it would have taken longer to see
an effect. It is of note that two other
groups have seen effects on reducing Ab
plaques with anti-pyroglutamate Ab anti-
bodies (Frost et al., 2012; Wirths et al.,
2010), though these antibodies differ in
their properties in comparison to mE8. In
terms of the lack of efficacy of the 3D6
antibody in removing pre-existing pla-
ques, DeMattos et al. (2012) interpreted
this to being due to 3D6 becoming bound
to monomeric Ab with saturation in the
microenvironment around the plaques,
not allowing amyloid plaque binding and
target engagement. Recent studies, how-
ever, suggest that the amount of mono-
meric, soluble Ab in the interstitial fluid of
the brain is decreased, not increased, in
the presence of amyloid plaques (Hong
et al., 2011; Roh et al., 2012). This is prob-
ably due to the sequestration of mono-
meric Ab into plaques. It is possible that
there are soluble monomeric or more
likely oligomeric forms of Ab that are
bound or loosely associated with plaques
that are not detected in the interstitial fluid
of the brain with current methods. Theo-
retically, 3D6 could bind to these forms
of Ab, resulting in saturation and preven-
tion of plaque binding. It is also possible
that there is not more soluble Ab around
plaques preventing the effect of 3D6 but
that the antibody simply has lower affinityfor certain forms of aggregated Ab or
lacks certain features that are needed
to decrease existing plaques once a
threshold level of Ab accumulation is
reached. Follow-up studies could be per-
formed in which soluble forms of Ab are
measured in the interstitial fluid of the
brain after administration of anti-Ab anti-
bodies to determine whether antibodies
are influencing soluble Ab differently in
the presence or absence of amyloid
plaques and to see whether this predicts
in any way the effects of anti-Ab anti-
bodies on plaque removal or functional
improvement.
The Ab plaque-specific mE8 antibody
might be an attractive candidate therapy
to consider for secondary prevention
trials for individuals with preclinical AD
as well as for treatments of individuals
with very mild dementia due to AD. Since
those with preclinical AD and mild cogni-
tive impairment or very mild dementia
due to AD already have substantial Ab
deposition in their brain (Jack et al.,
2010; Perrin et al., 2009), this type of treat-
ment targeting pre-existing Ab plaques
might be quite promising as a disease
modifying treatment.
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